The regulation of neovascularization by matrix metalloproteinases and their inhibitors

Stem Cells

Volumn 15, Issue 3, 1997, Pages 180-189

  Moses, Marsha A ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Angiogenesis inhibitors; MMPs; Proteolytic enzyme; TIMPs

Indexed keywords

ANGIOGENESIS INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANGIOGENESIS; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SYNTHESIS; EYE DISEASE; HUMAN; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR;

EID: 0030911308     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.150180     Document Type: Review

References (88)

1. Hobson B, Denekamp J. Endothelial proliferation in tumors and normal tissues: continuous labelling studies. Br J Cancer 1984;49:405-413.
2. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987;235:442-447.
3. Herron GS, Banda MJ, Clark EJ et al. Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem 1986;261:2814-2818.
4. Pepper MS, Montesano R. Proteolytic balance and capillary morphogenesis. Cell Differ Dev 1990;32:319-328.
5. Montesano R, Pepper MS, Mohle-Steinlein U et al. Increased proteolytic activity is responsible for the aberrant morphogenic behavior of endothelial cells expressing the middle T oncogene. Cell 1990:62:435-445.
6. Moses MA, Langer R. A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem 1991;47:1-6.
7. Liotta LA, Steeg PS, Stetler-Stevenson W. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-336.
8. Ingber DE, Madri JA, Folkman J. A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology 1986;119:1768-1775.
9. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enz Prot 1996;49:117-137.
10. Pepper MS, Montesano R, Mandriota SJ et al. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enz Prot 1996;49:138-162.
11. Risau W, Lemmon V. Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev Biol 1988;125:441-450.
12. Risau W. Embryonic angiogenesis factors. Pharmacol Ther 1991;51:371-376.
13. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 1977;14:53-65.
14. Kalebic T, Garbisa S, Glaser B et al. Basement membrane collagen: degradation by migrating endothelial cells. Science 1983;221:281-283.
15. Moses MA, Langer R. Angiogenesis inhibitors. Biotechnology 1991;9:630-639.
16. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990;1032:89-118.
17. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985;230:1375-1378.
18. Nguyen M, Shing Y, Folkman J. Quantitation of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane. Microvasc Res 1994;47:31-40.
19. Gimbrone M, Cotran R, Folkman J. Tumor growth neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974;52:413-427.
20. Mutan VR, Auerbach R. Angiogenesis in the mouse cornea. Science 1979;205:1418-1419.
21. Fournier GA, Lutty GA, Watt S et al. A corneal micropocket assay for angiogenesis in the rat eye. Invest Ophthalmol Vis Sei 1981;21:351-354.
22. Kenyon BM, Voest EE, Chen CC et al. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996;37:1625-1632.
23. Matrisian L. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121-125.
24. Woessner JF. The family of matrix metalloproteinases. Ann NY Acad Sci 1994;732:11-21.
25. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol 1995;7:728-735.
26. Docherty AJP, Lyons A, Smith BJ et al. Sequence of human tissue inhibitors of metalloproteinases and its identity to erythroid potentiating activity. Nature 1985;318:66-69.
27. Carmichael DF, Sommer A, Thompson RC et al. Primary structure and cDNA cloning of human fibroblast collagenase inhibitor. Proc Natl Acad Sci USA 1986;83:2407-2411.
28. Murray JB, Allison K, Sudhalter J et al. Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor. J Biol Chem 1986;261:4154-4159.
29. Stetler-Stevenson WG, Krutzch HC, Liotta LA. Tissue inhibitor of metalloproteinases (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem 1989;264:17374-17378.
30. DeClerck TA, Yean TD, Ratzkin BJ et al. Purification and characterization of two related but distinct metalloproteinase inhibitors secreted by bovine aortic endothelial cells. J Biol Chem 1989;264:17445-17453.
31. Pavloff N, Staskus PW, Kishnani NS et al. A new inhibitor of metalloproteinases from chicken: ChIMP-3. J Biol Chem 1992;67:17321-17326.
32. Williamson RA, Martson FAO, Angal S et al. Disulfide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem J 1990;268:267-274.
33. Cawston TE, Murphy G, Mercer E et al. The interaction of purified rabbit bone collagenase with purified rabbit bone metalloproteinase inhibitor. Biochem J 1983;211:313-318.
34. Welgus HG, Jeffery JJ, Eisen AZ et al. Human skin fibroblast collagenase: interaction with substrate and inhibitor. Coll Relat Res 1985;5:167-179.
35. Murphy G, Koklitis P, Carne AF. Dissociation of tissue inhibitor of metalloproteinases (TIMP) from enzyme complexes yield fully active inhibitor. Biochem J 1989;261:1031-1034.
36. Ward RV, Hembry RM, Reynolds JJ et al. The purification of tissue inhibitor of metalloproteinase-2 from its 72 kDa progelatinase complex. Demonstration of biochemical similarities. Biochem J 1991;278:179-187.
37. Howard EW, Bullen EC, Banda MJ. Preferential inhibition of 72-and 92-kDa gelatinases by tissue inhibitors of metalloproteinase-2. J Biol Chem 1991;266:13064-13069.
38. Goldberg GI, Manner BL, Grant GA et al. Human 72-kDa type IV collagenase forms a complex with a tissue inhibitor of metalloproteinase designated TIMP-2. Proc Natl Acad Sci USA 1989;86:8207-8211.
39. Wilhelm SM, Collier IE, Manner BL et al. SV40-transformed human fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989;264:17213-17221.
40. Khokha R, Waterhouse P, Yagel S et al. Antisense RNA-induced reduction of murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 1989;243:947-950.
41. Hicks NJ, Ward RV, Reynolds JJ. A fibrosarcoma model derived from mouse embryo cells: growth properties and secretion of collagenase and a metalloproteinase inhibitor (TIMP) by tumor cell lines. Int J Cancer 1984;33:835-844.
42. Schultz RM, Silberman S, Percky B. Inhibition of human recombinant tissue inhibitor of metalloproteinases of human amnion invasion by lung colonization by murine B16-F10 melanoma cells. Cancer Res 1988;48:5539-5545.
43. DeClerck YA, Perez N, Shimada H et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992;52:701-708.
44. Gasson JC, Golde DW, Kaufman SB et al. Molecular characterization and expression of the gene encoding human erythroid-potentiating activity. Nature 1985;315:768-771.
45. Alvalos BR, Kaufman SE, Tomonaga M et al. K562 cells produce and respond to human erythroid-potentiating activity. Blood 1988;71:1720-1725.
46. Hayakawa T, Yamashita K, Tanzawa K et al. Growth-promoting activity of tissue inhibitor of metalloproteinase-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992;298:29-32.
47. Bertaux B, Homebeck W, Eisen AZ et al. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 1991;97:679-685.
48. Bodden MK, Harber GJ, Birkedal-Hansen B et al. Functional domains of human TIMP-I (tissue inhibitor of metalloproteinases). J Biol Chem 1994;269:18943-18952.
49. Montesano R, Orci L, Vassalli P. In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 1983;97:1648-1652.
50. Moscatelli D, Presta M, Rifkin DB. Tetradecanoyl phorbol acetate stimulates latent collagenase production by cultured human endothelial cells. Cell 1980;20:343-351.
51. Gross JL, Moscatelli D, Jaffe EA et al. Plasminogen activator and collagenase production by cultured capillary endothelial cells. J Cell Biol 1982;95:974-981.
52. Herron GS, Werb Z, Dwyer D et al. Secretion of metalloproteinases by stimulated capillary endothelial cells. I. Production of procollagenase and prostromelysin exceeds expression of proteolytic activity. J Biol Chem 1986;261:2810-2813.
53. Unemori EN, Bouhana KS, Werb Z. Vectorial secretion of extracellular matrix proteins, matrix degrading proteinases and tissue inhibitor of metalloproteinases by endothelial cells. J Biol Chem 1990;265:445-451.
54. Fisher C, Gilbertson-Beadling S, Powers EA et al. Interstitial collagenase is required for angiogenesis in vitro. Dev Biol 1994;162:499-510.
55. Taraboletti G, Garafola A, Belotti D et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995;87:293-298.
56. Unemori EN, Ferrara N, Baurer EA et al. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1991;153:557-562.
57. Mignatti P, Tsuboi R, Robbins E et al. In vitro angiogenesis on the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J Cell Biol 1989;108:671-678.
58. Hanemaaijer R, Koolwijk P, Le Clercq L et al. Regulation of matrix metalloproteinase expression in human vein microvascular endothelial cells. Biochem J 1993;296:803-809.
59. Braunhut SJ, Gudas LJ, Kurokawa T et al. Expression of FGF by F9 teratocarcinoma cells as a function of differentiation. J Cell Biol 1989;108:2467-2476.
60. Ingber D, Folkman J. Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 1988;59:44-51.
61. Braunhut SJ, Moses MA. Retinoids modulate endothelial cell production of matrix-degrading proteases and tissue inhibitors of metalloproteinases (TIMP). J Biol Chem 1994;269:13472-13479.
62. Paige K, Palomares M, D'Amore PA. Retinol-induced modification of the extracellular matrix of endothelial cells: its role in growth control. In Vitro Cell Dev Biol 1991;27:151-157.
63. Zucker S, Conner C, DiMassmo BI et al. Thrombin induces the activation of progelatinase A in vascular endothelial cells. J Biol Chem 1995;270:23730-23738.
64. Lewalle JM, Munaut C, Pichot B et al. Plasma membrane-dependent activation of gelatinase A in human vascular endothelial cells. J Cell Physiol 1995;165:475483.
65. Schnaper HW, Grant DS, Stetler-Stevenson WG et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993;156:235-246.
66. Brem H, Folkman J. Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 1975;41:427-439.
67. Eisenstein R, Kuettner KE, Neopolitan C et al. The resistance of certain tissues to invasion. III. Cartilage extracts inhibit the growth of fibroblasts and endothelial cells in culture. Am J Pathol 1975;81:337-347.
68. Sorgente N, Kuettner KE, Soble L et al. The resistance of certain tissues to invasion. II. Evidence for extractable factors in cartilage which inhibit invasion by vascularized mesenchyme. Lab Invest 1975;32:217-222.
69. Langer R, Brem H, Falterman R et al. Isolation of a cartilage factor that inhibits tumor neovascularization. Science 1976;193:70-72.
70. Langer R, Conn H, Vacanti J et al. Control of tumor growth by infusion of an angiogenesis inhibitor. Proc Natl Acad Sci USA 1980;77:4331-4335.
71. Montesano R, Orci L. Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell 1985;42:469-477.
72. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 1990;2488:1408-1410.
73. Moses MA, Sudhalter J, Langer R. Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J Cell Biol 1992;119:474-481.
74. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res 1991;51:672-675.
75. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993;157:351-358.
76. Takigawa M, Nishida Y, Suzuki F et al. Induction of angiogenesis in chick yolk-sac membrane by polyamines and its inhibition by tissue inhibitors of metalloproteinases (TIMP-I and TIMP-2). Biochem Biophys Res Commun 1990;171:1264-1271.
77. Levi E, Fridman R, Miao H et al. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci USA 1996;93:7069-7074.
78. Johnson MD, Kim HC, Chesler L et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994;160:194-202.
79. Emmert-Buck MR, Emonard HP, Corcoran ML et al. Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEBS Lett 1995;364:28-32.
80. Gearing AJH, Beckett P, Christodoulou M et al. Processing of tumor necrosis factor-alpha precursor by metalloproteinases. Nature 1994;370:555-557.
81. McGeehan GM, Becherer JD, Bast RC et al. Regulation of tumor necrosis-alpha processing by a metalloproteinase inhibitor. Nature 1994;370:558-561.
82. Mohler KM, Sleath PR, Fitzner JN et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994;370:218-220.
83. Crowe P, Walter BN, Mohler KM et al. A metalloproteinase inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med 1995;181:1205-1210.
84. Frater-Schroder M, Risau W, Hallman R et al. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro. Proc Natl Acad Sci USA 1987;84:5277-5281.
85. Arribas J, Coodly L, Vollmer P et al. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem 1996;271:11376-11382.
86. O'Reilly MS, Holmgren L. Shing Y et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
87. Dong Z, Kumar R, Fidler LT. Generation of the angiogenesis inhibitor, angiostatin, by Lewis lung carcinoma is mediated by macrophage elastase. Proc Am Assoc Cancer Res 1996;37:403a.
88. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.